Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a subset of head and neck cancer known as oropharyngeal cancer. A rare ...

Organ preservation may be a viable option for select patients with locally advanced rectal cancer, according to the first results of the NO-CUT trial. The study investigated the efficacy of total ...

Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

Recent findings suggest no significant overall survival difference for patients with locally advanced esophageal squamous cell carcinoma who had neoadjuvant vs adjuvant therapy.

Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in perioperative setting in resectable non-small cell lung cancer Broad EU label with nine approved indications in solid ...

The surgical outcomes of colon cancer vary with its anatomical location. Neoadjuvant chemotherapy can aid in improving the postsurgical outcomes of both right and left colon cancer, decreasing the ...